-
Something wrong with this record ?
Cholic acid therapy in Zellweger spectrum disorders
K. Berendse, FC. Klouwer, BG. Koot, EM. Kemper, S. Ferdinandusse, KV. Koelfat, M. Lenicek, FG. Schaap, HR. Waterham, FM. Vaz, M. Engelen, PL. Jansen, RJ. Wanders, BT. Poll-The,
Language English Country Netherlands
Document type Journal Article
NLK
ProQuest Central
from 1999-02-01 to 2018-11-30
Medline Complete (EBSCOhost)
from 2009-08-01 to 1 year ago
Health & Medicine (ProQuest)
from 1999-02-01 to 2018-11-30
- MeSH
- Bilirubin blood MeSH
- Child MeSH
- Adult MeSH
- Liver metabolism MeSH
- Cholic Acid blood therapeutic use MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Adolescent MeSH
- Young Adult MeSH
- Liver Diseases drug therapy metabolism MeSH
- PHEX Phosphate Regulating Neutral Endopeptidase metabolism MeSH
- Child, Preschool MeSH
- Transaminases blood MeSH
- Zellweger Syndrome blood drug therapy metabolism MeSH
- Bile Acids and Salts metabolism MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
INTRODUCTION: Zellweger spectrum disorders (ZSDs) are characterized by a failure in peroxisome formation, caused by autosomal recessive mutations in different PEX genes. At least some of the progressive and irreversible clinical abnormalities in patients with a ZSD, particularly liver dysfunction, are likely caused by the accumulation of toxic bile acid intermediates. We investigated whether cholic acid supplementation can suppress bile acid synthesis, reduce accumulation of toxic bile acid intermediates and improve liver function in these patients. METHODS: An open label, pretest-posttest design study was conducted including 19 patients with a ZSD. Participants were followed longitudinally during a period of 2.5 years prior to the start of the intervention. Subsequently, all patients received oral cholic acid and were followed during 9 months of treatment. Bile acids, peroxisomal metabolites, liver function and liver stiffness were measured at baseline and 4, 12 and 36 weeks after start of cholic acid treatment. RESULTS: During cholic acid treatment, bile acid synthesis decreased in the majority of patients. Reduced levels of bile acid intermediates were found in plasma and excretion of bile acid intermediates in urine was diminished. In patients with advanced liver disease (n = 4), cholic acid treatment resulted in increased levels of plasma transaminases, bilirubin and cholic acid with only a minor reduction in bile acid intermediates. CONCLUSIONS: Oral cholic acid therapy can be used in the majority of patients with a ZSD, leading to at least partial suppression of bile acid synthesis. However, caution is needed in patients with advanced liver disease due to possible hepatotoxic effects.
Department of Pharmacy Academic Medical Center University of Amsterdam Amsterdam The Netherlands
Department of Surgery Maastricht University Amsterdam The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017132
- 003
- CZ-PrNML
- 005
- 20180515103232.0
- 007
- ta
- 008
- 180515s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10545-016-9962-9 $2 doi
- 035 __
- $a (PubMed)27469511
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Berendse, Kevin $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 245 10
- $a Cholic acid therapy in Zellweger spectrum disorders / $c K. Berendse, FC. Klouwer, BG. Koot, EM. Kemper, S. Ferdinandusse, KV. Koelfat, M. Lenicek, FG. Schaap, HR. Waterham, FM. Vaz, M. Engelen, PL. Jansen, RJ. Wanders, BT. Poll-The,
- 520 9_
- $a INTRODUCTION: Zellweger spectrum disorders (ZSDs) are characterized by a failure in peroxisome formation, caused by autosomal recessive mutations in different PEX genes. At least some of the progressive and irreversible clinical abnormalities in patients with a ZSD, particularly liver dysfunction, are likely caused by the accumulation of toxic bile acid intermediates. We investigated whether cholic acid supplementation can suppress bile acid synthesis, reduce accumulation of toxic bile acid intermediates and improve liver function in these patients. METHODS: An open label, pretest-posttest design study was conducted including 19 patients with a ZSD. Participants were followed longitudinally during a period of 2.5 years prior to the start of the intervention. Subsequently, all patients received oral cholic acid and were followed during 9 months of treatment. Bile acids, peroxisomal metabolites, liver function and liver stiffness were measured at baseline and 4, 12 and 36 weeks after start of cholic acid treatment. RESULTS: During cholic acid treatment, bile acid synthesis decreased in the majority of patients. Reduced levels of bile acid intermediates were found in plasma and excretion of bile acid intermediates in urine was diminished. In patients with advanced liver disease (n = 4), cholic acid treatment resulted in increased levels of plasma transaminases, bilirubin and cholic acid with only a minor reduction in bile acid intermediates. CONCLUSIONS: Oral cholic acid therapy can be used in the majority of patients with a ZSD, leading to at least partial suppression of bile acid synthesis. However, caution is needed in patients with advanced liver disease due to possible hepatotoxic effects.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a žlučové kyseliny a soli $x metabolismus $7 D001647
- 650 _2
- $a bilirubin $x krev $7 D001663
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kyselina cholová $x krev $x terapeutické užití $7 D019826
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a nemoci jater $x farmakoterapie $x metabolismus $7 D008107
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a neutrální endopeptidasa regulující fosfáty $x metabolismus $7 D053402
- 650 _2
- $a transaminasy $x krev $7 D000637
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a Zellwegerův syndrom $x krev $x farmakoterapie $x metabolismus $7 D015211
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Klouwer, Femke C C $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Koot, Bart G P $u Department of Pediatric Gastroenterology, Emma Children's hospital/ Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Kemper, Elles M $u Department of Pharmacy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Ferdinandusse, Sacha $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Koelfat, Kiran V K $u Department of Surgery, Maastricht University, Amsterdam, The Netherlands.
- 700 1_
- $a Lenicek, Martin $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Schaap, Frank G $u Department of Surgery, Maastricht University, Amsterdam, The Netherlands.
- 700 1_
- $a Waterham, Hans R $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Vaz, Frédéric M $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Engelen, Marc $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
- 700 1_
- $a Jansen, Peter L M $u Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Wanders, Ronald J A $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Poll-The, Bwee Tien $u Department of Pediatric Neurology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. b.t.pollthe@amc.uva.nl.
- 773 0_
- $w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 39, č. 6 (2016), s. 859-868
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27469511 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515103406 $b ABA008
- 999 __
- $a ok $b bmc $g 1300756 $s 1013972
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 39 $c 6 $d 859-868 $e 20160728 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
- LZP __
- $a Pubmed-20180515